Idexx Laboratories (IDXX) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Feb 1, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Sharon E. Underberg, Evp, Gc & Corporate Secretary sold 6,348 shares at $688.25 ($4.4M).
- Trade date
- Nov 4, 2026
- Disclosed to the SEC
- Nov 5, 2026
- Type
- Sale (code S)
Read the original SEC filing ↗All IDXX insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
IDXX insider transactions (Form 4)
Open-market purchases and sales. 93 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 5SEC | Sharon E. UnderbergEvp, Gc & Corporate Secretary | Sell | 6,3489,727 held (−39%) | $688.25 | $4.4M | +0.4% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 4,54096,716 held (−4%) | $701.36 | $3.2M | -1.5% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 4,075102,923 held (−4%) | $699.33 | $2.8M | -1.2% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 3,95090,630 held (−4%) | $703.45 | $2.8M | -1.8% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 2,13694,580 held (−2%) | $702.21 | $1.5M | -1.6% | — |
| Nov 5SEC | Michael LanePresident | Sell | 2,0595,753 held (−26%) | $689.70 | $1.4M | +0.2% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 1,945106,998 held (−2%) | $698.26 | $1.4M | -1.0% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 1,84087,710 held (−2%) | $707.84 | $1.3M | -2.4% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 1,667101,256 held (−2%) | $700.33 | $1.2M | -1.3% | — |
| Nov 5SEC | Michael LanePresident | Sell | 1,6774,076 held (−29%) | $687.46 | $1.2M | +0.5% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 1,50184,909 held (−2%) | $710.12 | $1.1M | -2.7% | — |
| Nov 5SEC | Sharon E. UnderbergEvp, Gc & Corporate Secretary | Sell | 1,5038,224 held (−15%) | $689.05 | $1.0M | +0.3% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 1,30086,410 held (−1%) | $709.00 | $922K | -2.5% | — |
| Nov 5SEC | Sharon E. UnderbergEvp, Gc & Corporate Secretary | Sell | 1,0557,169 held (−13%) | $690.02 | $728K | +0.1% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 84089,550 held (−1%) | $707.00 | $594K | -2.3% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 77584,134 held (−1%) | $711.31 | $551K | -2.9% | — |
| Nov 5SEC | Daniel M. JuniusDirector | Sell | 7002,861 held (−20%) | $705.78 | $494K | -2.1% | — |
| Nov 5SEC | Daniel M. JuniusDirector | Sell | 5002,361 held (−17%) | $701.68 | $351K | -1.5% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 33183,803 held (−0%) | $711.95 | $236K | -2.9% | — |
| Nov 5SEC | Jonathan Jay MazelskyChair | Sell | 24090,390 held (−0%) | $705.59 | $169K | -2.1% | — |
| Nov 5SEC | Michael LanePresident | Sell | 2437,812 held (−3%) | $687.85 | $167K | +0.5% | — |
| Sep 9SEC | Lawrence D. KingsleyDirector | Sell | 2,2039,568 held (−19%) | $532.08 | $1.2M | +29.9% | — |
| Mar 5SEC | Nimrata HuntPresident | Sell | 1,75818,141 held (−9%) | $634.57 | $1.1M | +8.9% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 3,66091,254 held (−4%) | $658.92 | $2.4M | +4.9% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 2,85988,395 held (−3%) | $659.75 | $1.9M | +4.7% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 2,86094,914 held (−3%) | $657.84 | $1.9M | +5.0% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 2,58983,606 held (−3%) | $663.04 | $1.7M | +4.2% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 1,669102,887 held (−2%) | $652.49 | $1.1M | +5.9% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 1,48899,117 held (−1%) | $655.85 | $976K | +5.4% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 1,34397,774 held (−1%) | $656.85 | $882K | +5.2% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 1,281105,651 held (−1%) | $650.67 | $834K | +6.2% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 1,20087,195 held (−1%) | $661.10 | $793K | +4.5% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 1,171101,716 held (−1%) | $653.68 | $765K | +5.7% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 1,111100,605 held (−1%) | $654.63 | $727K | +5.5% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 1,095104,556 held (−1%) | $651.49 | $713K | +6.1% | — |
| Mar 2SEC | Jonathan Jay MazelskyCEO, President | Sell | 1,00086,195 held (−1%) | $662.16 | $662K | +4.3% | — |
| Feb 27SEC | Nimrata HuntPresident | Sell | 2,69319,899 held (−12%) | $661.54 | $1.8M | +4.4% | — |
| Feb 19SEC | Michael G. EricksonPresident | Sell | 2,69413,422 held (−17%) | $628.22 | $1.7M | +10.0% | — |
| Feb 19SEC | Michael G. EricksonPresident | Sell | 1,28816,116 held (−7%) | $626.26 | $807K | +10.3% | — |
| Feb 19SEC | Sophie V. VandebroekDirector | Sell | 9451,167 held (−45%) | $628.65 | $594K | +9.9% | — |
| Feb 19SEC | Michael G. EricksonPresident | Sell | 68912,733 held (−5%) | $629.09 | $433K | +9.8% | — |
| Feb 19SEC | Sophie V. VandebroekDirector | Sell | 519648 held (−44%) | $628.56 | $326K | +9.9% | — |
| Feb 19SEC | Michael G. EricksonPresident | Sell | 45617,608 held (−3%) | $623.76 | $284K | +10.8% | — |
| Feb 19SEC | Michael G. EricksonPresident | Sell | 20417,404 held (−1%) | $625.24 | $128K | +10.5% | — |
| Feb 19SEC | Michael G. EricksonPresident | Sell | 4012,693 held (−0%) | $629.86 | $25K | +9.7% | — |
| Feb 11SEC | George FennellPresident | Sell | 2,8099,863 held (−22%) | $649.26 | $1.8M | +6.4% | — |
| Feb 11SEC | George FennellPresident | Sell | 2,78214,698 held (−16%) | $646.23 | $1.8M | +6.9% | — |
| Feb 11SEC | George FennellPresident | Sell | 2,16117,480 held (−11%) | $645.25 | $1.4M | +7.1% | — |
| Feb 11SEC | George FennellPresident | Sell | 1,13020,038 held (−5%) | $643.00 | $727K | +7.5% | — |
| Feb 11SEC | George FennellPresident | Sell | 1,06013,638 held (−7%) | $647.21 | $686K | +6.8% | — |
| Feb 11SEC | George FennellPresident | Sell | 96612,672 held (−7%) | $648.78 | $627K | +6.5% | — |
| Feb 11SEC | George FennellPresident | Sell | 39719,641 held (−2%) | $644.02 | $256K | +7.3% | — |
| Feb 11SEC | George FennellPresident | Sell | 409,823 held (−0%) | $650.32 | $26K | +6.2% | — |
| Nov 10SEC | Nimrata HuntPresident | Sell | 5,11425,460 held (−17%) | $702.20 | $3.6M | -1.6% | — |
| Nov 10SEC | Nimrata HuntPresident | Sell | 1,46822,527 held (−6%) | $704.87 | $1.0M | -2.0% | — |
| Nov 10SEC | Nimrata HuntPresident | Sell | 1,46523,995 held (−6%) | $703.73 | $1.0M | -1.8% | — |
| Nov 10SEC | Nimrata HuntPresident | Sell | 1,37821,149 held (−6%) | $705.54 | $972K | -2.1% | — |
Similar past setups: not applicable. IDXX has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with IDXX in the Research Lab
IDXX has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Idexx Laboratories insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 9 sold $58.4M of IDXX stock on the open market; P/E 46.9 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
IDXX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $27.4M | 21 |
| Q3 2026 | — | 0 | $1.2M | 1 |
| Q2 2026 | — | 0 | — | 0 |
| Q1 2026 | — | 0 | $29.9M | 31 |
| Q4 2025 | — | 0 | $6.6M | 4 |
Valuation, profit and volume
Source: Yahoo Finance, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Idexx Laboratories insiders reported open-market purchases totaling $0, while 9 insiders reported sales totaling $58.4M. 0 of 57 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
IDXX earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Nov 2, 2026 | +0.7% | None | +21.9%S&P -0.2% | pending |
| Aug 4, 2026 | +0.1% | None | +3.0%S&P +1.6% | -8.4% |
| May 5, 2026 | -4.4% | None | +2.9%S&P +2.2% | -2.9% |
| Feb 2, 2026 | -5.9% | None | -5.7%S&P -0.4% | -2.2% |
| Nov 3, 2025 | -1.2% | None | +14.7%S&P -1.0% | -0.6% |
| Aug 4, 2025 | +3.2% | None | +19.9%S&P +1.0% | -0.2% |
| May 1, 2025 | +7.1% | None | +9.1%S&P +2.2% | +8.8% |
| Feb 3, 2025 | -1.5% | None | +10.2%S&P -0.0% | -7.7% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
IDXX short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Insiders at Idexx Laboratories
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Jonathan Jay MazelskyChair | — | $33.0M | Nov 18, 2026 | — | — |
| Nimrata HuntPresident | — | $9.5M | Mar 5, 2026 | — | — |
| George FennellPresident | — | $7.3M | Nov 12, 2026 | — | — |
| Sharon E. UnderbergEvp, Gc & Corporate Secretary | — | $6.1M | Nov 5, 2026 | — | — |
| Michael G. EricksonPresident | — | $3.4M | Feb 19, 2026 | — | — |
| Michael LanePresident | — | $2.7M | Nov 20, 2026 | — | — |
| Lawrence D. KingsleyDirector | — | $1.2M | Sep 9, 2026 | — | — |
| Sophie V. VandebroekDirector | — | $920K | May 11, 2026 | — | — |
| Daniel M. JuniusDirector | — | $845K | Nov 5, 2026 | — | — |
| Joseph L. HooleyDirector | — | — | Nov 3, 2026 | — | — |
| Andrew EmersonCFO | — | — | Aug 24, 2026 | — | — |
| Karen PeacockDirector | — | — | May 11, 2026 | — | — |
| M. Anne SzostakDirector | — | — | May 11, 2026 | — | — |
| Michael SchreckPresident | — | — | Feb 17, 2026 | — | — |
| Martin Alexander SmithPresident | — | — | Feb 17, 2026 | — | — |
| Michael Perkins JohnsonPresident | — | — | Feb 17, 2026 | — | — |
Board links: companies that share insiders with IDXX
Directors and executives who filed Form 4s for IDXX and another company in the last 12 months.
- APTVAptiv Joseph L. Hooley Director here · Director at APTV · latest filing Nov 3, 2026
- DBXDropbox Karen Peacock Director here · Director at DBX · latest filing Jul 31, 2026
- MIRMirion Technologies Lawrence D. Kingsley Director here · Director at MIR · latest filing Sep 9, 2026
- PODDInsulet Jonathan Jay Mazelsky Chair here · Director at PODD · latest filing Nov 18, 2026
- RVTYRevvity Sophie V. Vandebroek Director here · Director at RVTY · latest filing May 11, 2026
- XOMExxonMobil Joseph L. Hooley Director here · Director at XOM · latest filing Nov 3, 2026
- XRAYDENTSPLY SIRONA Jonathan Jay Mazelsky Chair here · Director at XRAY · latest filing Nov 18, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
IDXX stock: common questions
Are Idexx Laboratories insiders buying IDXX stock?
No. No Idexx Laboratories insider reported an open-market purchase of IDXX in the past 12 months.
Are Idexx Laboratories insiders selling IDXX stock?
9 insiders reported sales worth $58.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is IDXX's P/E ratio?
IDXX trades at about 46.9 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is IDXX's 52-week range?
Over the past year IDXX has traded between $504.70 and $766.68. It last closed at $690.95 on Nov 19, 2026.